Company: HURA
Filing Date: 2025-06-06
Form Type: 8-K
Source: 0001193125-25-137135
Chunk: 4

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 8-K
Item: Item 1.01
Chunk 4
---
 limitation, statements regarding, the satisfaction to the conditions to the completing the offering, the impact of the proceeds from the offering, TuHURA’sIFx-Hu2.0product candidate and anticipated Phase 3 trial, its tumor microenvironment modulators development program, its potential acquisition by merger of Kineta Inc. and the statements about Kineta’sVISTA-101development program and statements regarding the closing conditions for the transaction, TuHURA’s needs and expectations regarding its existing capital resources and its need for additional capital (including financing to complete the Kineta merger), and any developments or results in connection therewith and the anticipated regulatory pathway and timing of the foregoing development programs, studies and trials. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on the combined company’s website, and at www. sec. gov.

The forward-looking statements and other information contained in this Form8-Kare made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth under Item 1.01 is incorporated by reference into this Item 3.02.

Item 7.01 Regulation FD Disclosure.

On June 3, 2025, the Company issued a press release announcing the Offering, a copy of which is filed herewith as Exhibit 99.1 and is incorporated by reference. Subsequent to the issuance of the press release, the size and amount of the Offering were slightly adjusted, with the final offering and size amount disclosed above in this Form 8-K. The disclosure in this Item 7.01 (including the exhibit) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act”), or otherwise subject to the liabilities of Section 18 of the